Liraglutide 10mg

Liraglutide is a type of polypeptide that closely resembles the naturally occurring protein GLP-1 (glucagon-like peptide), which is made up of 31 amino acids. With a structure that is 97% similar to GLP-1, scientists often refer to it as a lipopeptide because it includes the amino acid arginine and a hexadecanoyl group.

Due to this close similarity, researchers believe that liraglutide may work in a manner that mimics GLP-1, a hormone naturally produced in the intestine. GLP-1 helps boost insulin production and slows the rate of stomach emptying after eating. Additionally, liraglutide may stimulate satiety centers in the brain, causing a person to feel full sooner. It may also encourage the pancreas to release more insulin from beta cells, which reduces blood sugar levels after meals and supports overall blood sugar management.

What is Liraglutide and How it Works?

Liraglutide peptide, just like GLP-1, can stimulate the incretin effect. Incretins are hormones released in the gut that help trigger the release of insulin, thereby reducing glucose levels in the blood. GLP-1 receptors, specifically, are on the outside of beta cells in the pancreas. If glp-1 peptides, or a similar chemical, such as liraglutide, is bound to these receptors, it makes the beta cells release insulin.

Interestingly, the effect of liraglutide is even greater when combined with other drugs. In a 2007 study, researchers treated an isolated rat pancreas with liraglutide along with a sulfonylurea. The study found that while GLP-1 did not produce a significant effect on insulin release at low glucose levels, the combination with sulfonylurea led to heightened insulin release.

Liraglutide Research

Liraglutide and Pancreatic Receptors

Researchers believe that liraglutide may have different effects on pancreatic alpha (α) and beta (β) cells, particularly on their influence on cell survival, cell death (apoptosis), and secretory properties.

In α-cell experiments (using the α-TC1-6 cell line), Liraglutide has been shown to boost levels of miR-375, which increases cell death by blocking the cAMP-PKA signaling pathway. This reduces glucagon secretion from α-cells. Since glucagon is a hormone that elevates blood sugar, reducing its secretion can help test subjects effectively control their blood sugar levels. It also lowers cAMP levels, which consequently reduces the activity of the cAMP-PKA pathway.

In contrast, in β-cells (tested using the β-TC-tet cell line), this peptide seems to activate the cAMP-PKA pathway, which reduces miR-375 expression and promotes cell survival. This process may have the potential to increase insulin secretion, while its effects depend on liraglutide concentration. We can conclude that these findings suggest that liraglutide can enhance β-cell function while suppressing α-cell activity, possibly through divergent molecular mechanisms through the cAMP-PKA pathway and miR-375 regulation.

Liraglutide and Gastric Motility

Studies have shown that with liraglutide administration, the time it takes for the stomach to empty can be decreased by approximately 23% compared to a placebo. This indicates that liraglutide is capable of slowing gastric emptying initially. However, when examining the overall five-hour period (AUC0–300 min), researchers did not find a significant difference between patients who received liraglutide and those who received a placebo. Although the long-term effect is not significant, this short-term slowing of stomach emptying after meals may still help trigger early sensations of fullness.

Researchers believe liraglutide slows gastric emptying via a multifaceted sequence of mechanisms. These involve effects on neural pathways that activate GLP-1 receptors in both the central nervous system (CNS) and the peripheral nervous system. The mechanism begins perhaps with liraglutide stimulating GLP-1 receptors in specialized stomach and intestinal endocrine cells, which would then normally react to meals by secreting GLP-1. Liraglutide, so to speak, imitates this usual response, but increases its effects.

Once stimulated, these receptors have the potential to send signals through the enteric nervous system, which helps regulate the movement of the digestive tract. Through the stimulation of these pathways, Liraglutide appears to slow the stomach's contractions and delay the rate at which its contents move into the small intestine. At the same time, this peptide also acts through the vagus nerve, which sends signals to the brain that also slow gastric emptying by altering autonomic nervous system outputs directed toward the stomach.

Liraglutide and Central Satiety-Inducing Mechanisms

Some studies suggest that liraglutide's ability to cause weight loss in animal models may not be affected only by GLP-1 receptors (GLP-1Rs) located in areas such as the vagus nerve, area postrema, and paraventricular nucleus. Instead, researchers suggest that liraglutide can regulate weight through mechanisms independent of GLP-1Rs, using more advanced neural networks outside of the traditional GLP-1R pathways.

In experiments, Liraglutide was attached to a fluorescent tag and injected into mice; scientists were able to detect its presence in specific parts of the brain known as the circumventricular organs. This suggests that liraglutide can directly target brain mechanisms involved in regulating hunger and maintaining weight. One extremely significant area of interest is the arcuate nucleus (ARC) of the hypothalamus, which plays a crucial role in regulating energy balance and hunger.

The ARC contains two important sets of neurons: one that releases proopiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART), both of which inhibit appetite, and a set that releases neuropeptide Y (NPY) and agouti-related peptide (AgRP), which stimulate appetite. Liraglutide appears to bind selectively to neurons in the ARC and other areas of the hypothalamus in which GLP-1Rs are expressed. Surprisingly, selective binding occurred only in intact GLP-1 receptor models and not in mice deficient in their receptors, suggesting that the ARC is an important mediator of the anti-appetite effect of liraglutide through its interaction with GLP-1Rs within this brain region.

Liraglutide and Adipose Tissue Interactions

Scientists believe that liraglutide may act on fat tissue (adipose tissue) and affect the levels of vital hormones, such as leptin and peptide YY (PYY), both of which are involved in regulating energy balance and appetite. Adipose tissue isn't just a fat storage depot; it's also an endocrine organ that secretes hormones, and liraglutide may change its function.

Liraglutide may normalize leptin levels, possibly by changing this reduction or increasing the body's sensitivity to leptin, making it easier to maintain weight loss.

PYY, a hormone the gut releases after eating, has also been implicated in reducing appetite and increasing the feeling of fullness. Some research suggests that liraglutide may elevate PYY levels while suppressing hunger simultaneously. This action could partially explain why animals given liraglutide in trials under controlled conditions have shown reduced food intake and weight loss.

What is the Difference Between Liraglutide Semaglutide and Retatrutide

Both Liraglutide and Semaglutide are GLP-1 agonists, medications that tend to make the subjects of clinical trials lose weight. These medications differ in dosing as well as efficacy. For example, Liraglutide is administered daily and has been shown to reduce body weight by 5–6% in animal studies, while Semaglutide is administered weekly and can cause even greater weight loss. Retatrutide, currently being studied as a triple agonist (GLP-1, GIP, and glucagon receptors), has shown promising early research data suggesting a potential for significant weight reduction effects.

References:

• Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH, Taylor KL, Trautmann ME, Kim DD, Kendall DM. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. https://pubmed.ncbi.nlm.nih.gov/16776751/

• Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. https://pubmed.ncbi.nlm.nih.gov/29617660/

• Nauck MA, Meier JJ. Incretin hormones: Their role in health and disease. https://pubmed.ncbi.nlm.nih.gov/29479884/

• Secher A, Jelsing J, Baquero AF, Hecksher-Sørensen J, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. https://pubmed.ncbi.nlm.nih.gov/25202980/

• van Bloemendaal L, Ten Kulve JS, la Fleur SE, IJzerman RG, Diamant M. Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. https://pubmed.ncbi.nlm.nih.gov/25200291/

• Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. https://pubmed.ncbi.nlm.nih.gov/30930862/

• Holst JJ. The physiology of glucagon-like peptide 1. https://pubmed.ncbi.nlm.nih.gov/17928588/

• Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: the LEAD-6 trial. https://pubmed.ncbi.nlm.nih.gov/19515413/

• Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. https://pubmed.ncbi.nlm.nih.gov/9449682/

• Farr OM, Sofopoulos M, Tsoukas MA, et al. GLP-1 Receptors in Human Adipose Tissue: Functional and Clinical Implications. https://pubmed.ncbi.nlm.nih.gov/26910304/